52 results on '"Osterlund, A"'
Search Results
2. The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study
3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
4. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
5. Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study
6. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
7. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study
8. EGCG has Dual and Opposing Effects on the N-terminal Region of Self-associating α-synuclein Oligomers
9. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
10. Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey
11. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)
12. Motives for shelter camping. A survey-study on motivational differences across group composition and experience level
13. Do public subsidies and facility coverage matter for voluntary sports clubs?
14. Remote CB1 receptor antagonist administration reveals multiple sites of tonic and phasic endocannabinoid neuroendocrine regulation
15. Risk factors for postoperative myocardial infarct following cholecystectomy: a population-based study
16. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
17. 591P Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
18. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries
19. Drift and shift in the organizing vision career for personal health records: An investigation of innovation discourse dynamics
20. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
21. 607P Impact of primary tumour sidedness (PTS) on demographics, resectability, and outcome after metastasectomy +/- local ablative therapy (LAT), or systemic therapy in metastatic colorectal cancer patients (a RAXO substudy)
22. 606P Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
23. Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague–Dawley rats
24. Virtual reality: Avatars in human spaceflight training
25. PD-22 RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts
26. PD-19 Finnish population-based metastatic colorectal cancer data collection study – comparison with the prospective RAXO study
27. Lung metastasectomy for colorectal cancer in the PulMiCC randomised controlled trial – Authors’ reply
28. PD-14 Resectability, conversion, and resection rates with survival according to RAS and BRAF mutations in a prospective metastatic colorectal cancer study (liver-limited subgroup in the RAXO study)
29. SO-33 The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study
30. Hedgehog signalling: how to get from Smo to Ci and Gli
31. SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595)
32. SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients
33. 430P Prediction of pathologic complete response to preoperative (chemo)radiotherapy and/or chemotherapy in rectal cancer using clinical and imaging parameters
34. 410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
35. 394P Impact of gender on demographics, resectability, resections, systemic treatment, adverse events and outcomes in metastatic colorectal cancer (mCRC) patients (RAXO-study)
36. 345P The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study
37. SO-22 Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries
38. SO-18 Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial
39. Applied plant genomics: the secret is integration
40. PD-028 - Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study
41. SIOG2021-0142 - Computed tomography-assessed loss of muscle mass associates with functional measures in older cancer patients
42. 396P Resectability, resections, systemic treatment and outcomes in elderly metastatic colorectal cancer (mCRC) patients (the RAXO study)
43. 1826P Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: A global survey
44. SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
45. The role of COP1 in repression of Arabidopsis photomorphogenic development
46. P-80 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma
47. O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
48. P-098 - TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)
49. 601TiP - NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)
50. ID: 201: Live cell imaging-based studies of dynamics of antiviral signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.